These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 19632952)

  • 21. HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%.
    Shuter J; Sarlo JA; Kanmaz TJ; Rode RA; Zingman BS
    J Acquir Immune Defic Syndr; 2007 May; 45(1):4-8. PubMed ID: 17460469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions.
    Tinago W; O'Halloran JA; O'Halloran RM; Macken A; Lambert JS; Sheehan GJ; Mallon PW
    HIV Med; 2014 Apr; 15(4):224-32. PubMed ID: 24215370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
    Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
    J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PI monotherapy effective as maintenance.
    AIDS Patient Care STDS; 2005 Oct; 19(10):696. PubMed ID: 16232054
    [No Abstract]   [Full Text] [Related]  

  • 25. Antiviral activity and clinical efficacy of atazanavir in HIV-1-infected patients: a review.
    Gianotti N; Soria A; Lazzarin A
    New Microbiol; 2007 Apr; 30(2):79-88. PubMed ID: 17619250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients.
    Horberg M; Klein D; Hurley L; Silverberg M; Towner W; Antoniskis D; Kovach D; Mogyoros M; Blake W; Dobrinich R; Dodge W
    HIV Clin Trials; 2008; 9(6):367-74. PubMed ID: 19203902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758.
    Hicks CB; DeJesus E; Sloan LM; Sension MG; Wohl DA; Liao Q; Ross LL; Pakes GE; Pappa KA; Lancaster CT;
    AIDS Res Hum Retroviruses; 2009 Apr; 25(4):395-403. PubMed ID: 19320570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of efavirenz compared with ritonavir-boosted protease-inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/ml.
    Imaz A; Llibre JM; Navarro J; Curto J; Clotet B; Crespo M; Ferrer E; Saumoy M; Tiraboschi JM; Murillo O; Podzamczer D
    Antivir Ther; 2014; 19(6):569-77. PubMed ID: 24458091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short-term effect of ritonavir-boosted atazanavir in hepatitis B and/or C co-infected, treatment-experienced HIV patients.
    Pérez-Elías MJ; Gatell JM; Flores J; Santos J; Vera-Médez F; Clotet B; Moreno A; Pérez-Molina JA; Vendrell B; Serrano O
    HIV Clin Trials; 2009; 10(4):269-75. PubMed ID: 19723614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atazanavir exposure is effective during pregnancy regardless of tenofovir use.
    Colbers A; Hawkins D; Hidalgo-Tenorio C; van der Ende M; Gingelmaier A; Weizsäcker K; Kabeya K; Taylor G; Rockstroh J; Lambert J; Moltó J; Wyen C; Sadiq ST; Ivanovic J; Giaquinto C; Burger D;
    Antivir Ther; 2015; 20(1):57-64. PubMed ID: 24992294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
    Martínez E; Larrousse M; Llibre JM; Gutiérrez F; Saumoy M; Antela A; Knobel H; Murillas J; Berenguer J; Pich J; Pérez I; Gatell JM;
    AIDS; 2010 Jul; 24(11):1697-707. PubMed ID: 20467288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).
    Di Giambenedetto S; Fabbiani M; Colafigli M; Ciccarelli N; Farina S; Sidella L; D'Avino A; Mondi A; Cingolani A; Tamburrini E; Murri R; Navarra P; Cauda R; De Luca A
    J Antimicrob Chemother; 2013 Jun; 68(6):1364-72. PubMed ID: 23372058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful rescue therapy with darunabir (TMC114) in HIV-infected patients who have failed several ritonavir-boosted protease inhibitors.
    Poveda E; Blanco F; García-Gascó P; Alcolea A; Briz V; Soriano V
    AIDS; 2006 Jul; 20(11):1558-60. PubMed ID: 16847414
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir.
    Manosuthi W; Sungkanuparph S; Ruxrungtham K; Prasithsirikul W; Athichathanabadi C; Tantisiriwat W; Bowonwatanuwong C; Chumpathat N; Chaovavanich A
    J Acquir Immune Defic Syndr; 2008 Jan; 47(1):127-9. PubMed ID: 18156994
    [No Abstract]   [Full Text] [Related]  

  • 35. Superior virological efficacy of ritonavir-boosted protease inhibitor regimens compared to single protease inhibitor therapy.
    Lichterfeld M; Wöhrmann A; Schmeisser N; Fätkenheuer G; Salzberger B; Wyen C; Schmitz K; Sauerbruch T; Rockstroh JK
    Eur J Med Res; 2003 Feb; 8(2):56-60. PubMed ID: 12626282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
    Gallant JE; Koenig E; Andrade-Villanueva J; Chetchotisakd P; DeJesus E; Antunes F; Arastéh K; Moyle G; Rizzardini G; Fehr J; Liu Y; Zhong L; Callebaut C; Szwarcberg J; Rhee MS; Cheng AK
    J Infect Dis; 2013 Jul; 208(1):32-9. PubMed ID: 23532097
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.
    Raguin G; Chêne G; Morand-Joubert L; Taburet AM; Droz C; Le Tiec C; Clavel F; Girard PM;
    Antivir Ther; 2004 Aug; 9(4):615-25. PubMed ID: 15456093
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir.
    Masquelier B; Assoumou KL; Descamps D; Bocket L; Cottalorda J; Ruffault A; Marcelin AG; Morand-Joubert L; Tamalet C; Charpentier C; Peytavin G; Antoun Z; Brun-Vézinet F; Costagliola D;
    J Antimicrob Chemother; 2008 Jun; 61(6):1362-8. PubMed ID: 18390885
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients.
    Di Biagio A; Rosso R; Loregian A; Pagni S; Sormani MP; Cenderello G; Palù G; Viscoli C
    J Infect Chemother; 2012 Aug; 18(4):587-90. PubMed ID: 22422300
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection.
    Deeks ED
    Drugs; 2014 Feb; 74(2):195-206. PubMed ID: 24343782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.